当前期刊: European Journal of Heart Failure Go to current issue    加入关注   
显示样式:        排序: 导出
  • Predictors of sudden cardiac death in high‐risk patients following a myocardial infarction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-16
    Kieran F. Docherty; João Pedro Ferreira; Abhinav Sharma; Nicolas Girerd; John Gregson; Kevin Duarte; Mark C. Petrie; Pardeep S. Jhund; Kenneth Dickstein; Marc A. Pfeffer; Bertram Pitt; Patrick Rossignol; Faiez Zannad; John J.V. McMurray

    To develop a risk model for sudden cardiac death (SCD) in high‐risk acute myocardial infarction (AMI) survivors.

  • Use of sodium–glucose co‐transporter‐2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-11
    Javed Butler; Yehuda Handelsman; George Bakris; Subodh Verma

    Type 2 diabetes (T2D) is associated with an increased risk of heart failure (HF), with recent reports indicating that HF with preserved ejection fraction (HFpEF) may be more common than HF with reduced ejection fraction (HFrEF) in patients with T2D. T2D and HF result in worse outcomes than either disease alone. Sodium–glucose co‐transporter‐2 inhibitors (SGLT‐2is) have significantly improved HF outcomes in patients with T2D and may represent a new therapeutic alternative for patients with T2D at risk for or with HF. Current guidelines recommend prevention of HF through risk factor management. Once developed, treatment of HFrEF should include neurohormonal and haemodynamic modulations; however, there are no specific treatments available for HFpEF. SGLT‐2is are the first class of glucose‐lowering therapy to prevent HF in clinical trials and real‐world studies in patients with T2D (with or without established cardiovascular disease and with or without baseline HF). Mechanistic studies suggest that SGLT‐2is have beneficial effects on both systolic and diastolic function and additional systemic effects that could benefit HF outcomes. In patients with HFrEF, SGLT‐2i treatment as add‐on to standard HF therapy has had beneficial effects on HF outcomes, irrespective of T2D status. These results and those of ongoing outcomes trials with SGLT‐2is may help establish this drug class as a treatment for HF in patients with HFrEF and HFpEF, as well as HF in patients without T2D.

  • Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-09
    Alberto Aimo; James L. Januzzi; Giuseppe Vergaro; A. Mark Richards; Carolyn S.P. Lam; Roberto Latini; Inder S. Anand; Jay N. Cohn; Thor Ueland; Lars Gullestad; Pål Aukrust; Hans‐Peter Brunner‐La Rocca; Antoni Bayes‐Genis; Josep Lupón; Rudolf A. de Boer; Yasuchika Takeishi; Michael Egstrup; Ida Gustafsson; Hanna K. Gaggin; Kai M. Eggers; Kurt Huber; Greg D. Gamble; Lieng H. Ling; Kui Tong Gerard Leong; Poh Shuah Daniel Yeo; Hean Yee Ong; Fazlur Jaufeerally; Tze P. Ng; Richard Troughton; Robert N. Doughty; Claudio Passino; Michele Emdin

    N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), high‐sensitivity troponin T (hs‐TnT) and soluble suppression of tumorigenesis‐2 (sST2) predict outcome in chronic heart failure (HF). We assessed the influence of age on circulating levels and prognostic significance of these biomarkers.

  • Genetic risk and atrial fibrillation in patients with heart failure
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-09
    Mariëlle Kloosterman; Bernadet T. Santema; Carolina Roselli; Christopher P. Nelson; Andrea Koekemoer; Simon. P.R. Romaine; Isabelle C. Van Gelder; Carolyn S.P. Lam; Vicente A. Artola; Chim C. Lang; Leon L. Ng; Marco Metra; Stefan Anker; Gerasimos Filippatos; Kenneth Dickstein; Piotr Ponikowski; Pim van der Harst; Peter van der Meer; Dirk J. van Veldhuisen; Emelia J. Benjamin; Adriaan A. Voors; Nilesh J. Samani; Michiel Rienstra

    To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all‐cause mortality in patients with heart failure.

  • Hypertrophic cardiomyopathy: the future of treatment
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-09
    C. Vaughan Tuohy; Sanjiv Kaul; Howard K. Song; Babak Nazer; Stephen B. Heitner

    Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility, and reduced compliance. It is the most common inherited monogenic cardiac condition, affecting 0.2% of the population. Whereas currently available therapies for HCM have been effective in reducing morbidity, there remain important unmet needs in the treatment of both the obstructive and non‐obstructive phenotypes. Novel pharmacotherapies directly target the molecular underpinnings of HCM, while innovative procedural techniques may soon offer minimally‐invasive alternatives to current septal reduction therapy. With the advent of embryonic gene editing, there now exists the potential to correct underlying genetic mutations that may result in disease. This article details the recent developments in the treatment of HCM including pharmacotherapy, septal reduction procedures, mitral valve manipulation, and gene‐based therapies.

  • Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-09
    Patrick Rossignol; Kevin Duarte; Nicolas Girerd; Moez Karoui; John J.V. McMurray; Karl Swedberg; Dirk J. van Veldhuisen; Stuart Pocock; Kenneth Dickstein; Faiez Zannad; Bertram Pitt

    To assess the prognostic value of mineralocorticoid receptor antagonist (MRA) initiation and change in serum potassium (K+) during follow‐up in patients post‐acute myocardial infarction with left ventricular dysfunction or chronic heart failure (HF) and reduced ejection fraction (HFrEF).

  • Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-09
    Muhammad Shahzeb Khan; Muhammad Mustafa Memon; Mohammad H. Murad; Muthiah Vaduganathan; Stephen J. Greene; Michael Hall; Filippos Triposkiadis; Carolyn S.P. Lam; Amil M. Shah; Javed Butler; Sanjiv J. Shah

    Left atrial (LA) mechanical function may play a significant role in the development and progression of heart failure with preserved ejection fraction (HFpEF). We performed a systematic review and meta‐analysis to evaluate association of impaired LA function with outcomes in HFpEF.

  • Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-07
    Kevin Damman; Joost C. Beusekamp; Eva M. Boorsma; Henk P. Swart; Tom D.J. Smilde; Arif Elvan; J.W. Martijn van Eck; Hiddo J.L. Heerspink; Adriaan A. Voors

    Inhibition of sodium–glucose co‐transporter 2 (SGLT2) reduces the risk of death and heart failure (HF) admissions in patients with chronic HF. However, safety and clinical efficacy of SGLT2 inhibitors in patients with acute decompensated HF are unknown.

  • Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy?
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-07
    Maximilian L. Müller; Javed Butler; Bettina Heidecker

    Transthyretin amyloidosis (ATTR) is a rare, yet underdiagnosed disease characterized by progressive impairment of neurologic and cardiac function due to deposition of misfolded transthyretin. Despite great efforts, such as the introduction of orthotopic liver transplant, the devastating prognosis for both variant and wild‐type ATTR patients remained unchanged over the last decades, mainly due to a lack of specific therapies. Fortunately, recent years saw the introduction of promising targeted therapies, which aim to interfere with the deposition of misfolded transthyretin (TTR) at various stages of the cascade underlying ATTR progression. These include TTR tetramer stabilizers (tafamidis, diflunisal, epigallocatechin‐3‐gallate), TTR silencers (inotersen, patisiran) and fibril disruptors (monoclonal antibodies, doxycycline and tauroursodeoxycholic acid). In the context of this review we explain their mechanisms of action, analyse their efficacy on neurologic and cardiac function based on all clinical trials conducted to date and discuss their clinical applicability. Eventually suggestions for future clinical research into the field are provided.

  • Impact of remote monitoring on clinical outcomes for patients with heart failure and atrial fibrillation: results from the REM‐HF trial
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-07
    Rosita Zakeri; John M. Morgan; Patrick Phillips; Sue Kitt; G. Andre Ng; Janet M. McComb; Simon Williams; David J. Wright; Jaswinder S. Gill; Alison Seed; Klaus K. Witte; Martin R. Cowie;

    Studies of remote monitoring (RM) in heart failure (HF) speculate that patients with atrial fibrillation (AF) derive the greatest benefit. We compared the impact of RM vs. usual care on clinical outcomes for patients with and without AF enrolled in the Remote Management of Heart Failure Using Implanted Electronic Devices (REM‐HF) trial.

  • Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-07
    Wilfried Mullens; Kevin Damman; Jeffrey M. Testani; Pieter Martens; Christian Mueller; Johan Lassus; W.H. Wilson Tang; Hadi Skouri; Frederik H. Verbrugge; Francesco Orso; Loreena Hill; Ural Dilek; Mitcha Lainscak; Patrick Rossignol; Marco Metra; Alexandre Mebazaa; Petar Seferovic; Frank Ruschitzka; Andrew Coats

    Appropriate interpretation of changes in markers of kidney function is essential during the treatment of acute and chronic heart failure. Historically, kidney function was primarily assessed by serum creatinine and the calculation of estimated glomerular filtration rate. An increase in serum creatinine, also termed worsening renal function, commonly occurs in patients with heart failure, especially during acute heart failure episodes. Even though worsening renal function is associated with worse outcome on a population level, the interpretation of such changes within the appropriate clinical context helps to correctly assess risk and determine further treatment strategies. Additionally, it is becoming increasingly recognized that assessment of kidney function is more than just glomerular filtration rate alone. As such, a better evaluation of sodium and water handling by the renal tubules allows to determine the efficiency of loop diuretics (loop diuretic response and efficiency). Also, though neurohumoral blockers may induce modest deteriorations in glomerular filtration rate, their use is associated with improved long‐term outcome. Therefore, a better understanding of the role of cardio–renal interactions in heart failure in symptom development, disease progression and prognosis is essential. Indeed, perhaps even misinterpretation of kidney function is a leading cause of not attaining decongestion in acute heart failure and insufficient dosing of guideline‐directed medical therapy in general. This position paper of the Heart Failure Association Working Group on Cardio‐Renal Dysfunction aims at improving insights into the interpretation of renal function assessment in the different heart failure states, with the goal of improving heart failure care.

  • Functional mitral regurgitation and left atrial myopathy in heart failure with preserved ejection fraction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2020-01-07
    Maria Tamargo; Masaru Obokata; Yogesh N.V. Reddy; Sorin V. Pislaru; Grace Lin; Alexander C. Egbe; Rick A. Nishimura; Barry A. Borlaug

    Mild to moderate functional mitral regurgitation (MR) is common in patients with heart failure and preserved ejection fraction (HFpEF) where it is usually considered as an innocent bystander. We hypothesized that MR in HFpEF reflects greater left atrial (LA) myopathy, leading to more adverse haemodynamics and poorer exercise reserve.

  • Effects of serelaxin in patients admitted for acute heart failure: a meta‐analysis
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-30
    John R. Teerlink; Beth A. Davison; Gad Cotter; Aldo P. Maggioni; Naoki Sato; Ovidiu Chioncel; Georg Ertl; G. Michael Felker; Gerasimos Filippatos; Barry H. Greenberg; Peter S. Pang; Piotr Ponikowski; Christopher Edwards; Stefanie Senger; Sam L. Teichman; Olav Wendelboe Nielsen; Adriaan A. Voors; Marco Metra

    The effectiveness and safety of 48 h intravenous 30 μg/kg/day serelaxin infusion in acute heart failure (AHF) has been studied in six randomized, controlled clinical trials.

  • Rationale and design of the AFFIRM‐AHF trial: a randomised, double‐blind, placebo‐controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron‐deficient patients admitted for acute heart failure
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-28
    Piotr Ponikowski; Bridget‐Anne Kirwan; Stefan D. Anker; Maria Dorobantu; Jarosław Drozdz; Vincent Fabien; Gerasimos Filippatos; Teba Haboubi; Andre Keren; Irakli Khintibidze; Hans Kragten; Felipe A. Martinez; Theresa McDonagh; Marco Metra; Davor Milicic; José C. Nicolau; Marcus Ohlsson; Alexander Parhomenko; Domingo A. Pascual‐Figal; Frank Ruschitzka; David Sim; Hadi Skouri; Peter van der Meer; Ewa A. Jankowska

    Iron deficiency (ID) is a common co‐morbidity in heart failure (HF), associated with impaired functional capacity, poor quality of life and increased morbidity and mortality. Treatment with intravenous (i.v.) ferric carboxymaltose (FCM) has shown improvements in functional capacity, symptoms and quality of life in stable HF patients with reduced ejection fraction. The effect of i.v. iron supplementation on morbidity and mortality in patients hospitalised for acute HF (AHF) and who have ID has yet to be established. The objective of the present article is to present the rationale and design of the AFFIRM‐AHF trial (ClinicalTrials.gov NCT02937454) which will investigate the effect of i.v. FCM (vs. placebo) on recurrent HF hospitalisations and cardiovascular (CV) mortality in iron‐deficient patients hospitalised for AHF.

  • Association between systolic ejection time and outcomes in heart failure by ejection fraction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-21
    Priyesh A. Patel; Andrew P. Ambrosy; Matthew Phelan; Fawaz Alenezi; Karen Chiswell; Melissa K. Van Dyke; Jennifer Tomfohr; Narimon Honarpour; Eric J. Velazquez

    Worsening heart failure (HF) is associated with shorter left ventricular systolic ejection time (SET), but there are limited data describing the relationship between SET and clinical outcomes. Thus, the objective was to describe the association between SET and clinical outcomes in an ambulatory HF population irrespective of ejection fraction (EF).

  • A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-21
    Anders Hostrup Larsen; Niels Jessen; Helene Nørrelund; Lars Poulsen Tolbod; Hendrik Johannes Harms; Søren Feddersen; Flemming Nielsen; Kim Brøsen; Nils Henrik Hansson; Jørgen Frøkiær; Steen Hvitfeldt Poulsen; Jens Sörensen; Henrik Wiggers

    The present study tested the hypothesis that metformin treatment may increase myocardial efficiency (stroke work/myocardial oxygen consumption) in insulin‐resistant patients with heart failure and reduced ejection fraction (HFrEF) without diabetes.

  • Bone marrow‐derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4‐year follow‐up of the MSC‐HF trial
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-21
    Anders B. Mathiasen; Abbas A. Qayyum; Erik Jørgensen; Steffen Helqvist; Klaus F. Kofoed; Mandana Haack‐Sørensen; Annette Ekblond; Jens Kastrup

    The study assessed 4‐year outcomes of intramyocardial injections of autologous bone marrow‐derived mesenchymal stromal cells (MSCs) in patients with ischaemic heart failure.

  • Short‐term prognostic implications of serum and urine neutrophil gelatinase‐associated lipocalin in acute heart failure: findings from the AKINESIS study
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-21
    Nicholas Wettersten; Yu Horiuchi; Dirk J. van Veldhuisen; Christian Mueller; Gerasimos Filippatos; Richard Nowak; Christopher Hogan; Michael C. Kontos; Chad M. Cannon; Gerhard A. Müeller; Robert Birkhahn; Pam Taub; Gary M. Vilke; Olga Barnett; Kenneth McDonald; Niall Mahon; Julio Nuñez; Carlo Briguori; Claudio Passino; Alan Maisel; Patrick T. Murray

    Kidney impairment has been associated with worse outcomes in acute heart failure (AHF), although recent studies challenge this association. Neutrophil gelatinase‐associated lipocalin (NGAL) is a novel biomarker of kidney tubular injury. Its prognostic role in AHF has not been evaluated in large cohorts. The present study aimed to determine if serum NGAL (sNGAL) or urine NGAL (uNGAL) is superior to creatinine for predicting short‐term outcomes in AHF.

  • Impact of aspirin on takotsubo syndrome: a propensity score‐based analysis of the InterTAK Registry
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-20
    Fabrizio D'Ascenzo; Sebastiano Gili; Maurizio Bertaina; Mario Iannaccone; Victoria L. Cammann; Davide Di Vece; Ken Kato; Andrea Saglietto; Konrad A. Szawan; Antonio H. Frangieh; Beatrice Boffini; Margherita Annaratone; Annahita Sarcon; Rena A. Levinson; Jennifer Franke; L. Christian Napp; Milosz Jaguszewski; Michel Noutsias; Thomas Münzel; Maike Knorr; Susanne Heiner; Hugo A. Katus; Christof Burgdorf; Heribert Schunkert; Holger Thiele; Johann Bauersachs; Carsten Tschöpe; Burkert M. Pieske; Lawrence Rajan; Guido Michels; Roman Pfister; Alessandro Cuneo; Claudius Jacobshagen; Gerd Hasenfuß; Mahir Karakas; Wolfgang Koenig; Wolfgang Rottbauer; Samir M. Said; Ruediger C. Braun‐Dullaeus; Adrian Banning; Florim Cuculi; Richard Kobza; Thomas A. Fischer; Tuija Vasankari; K.E. Juhani Airaksinen; Grzegorz Opolski; Rafal Dworakowski; Philip MacCarthy; Christoph Kaiser; Stefan Osswald; Leonarda Galiuto; Filippo Crea; Wolfgang Dichtl; Wolfgang M. Franz; Klaus Empen; Stephan B. Felix; Clément Delmas; Olivier Lairez; Ibrahim El‐Battrawy; Ibrahim Akin; Martin Borggrefe; John D. Horowitz; Martin Kozel; Petr Tousek; Petr Widimský; Ekaterina Gilyarova; Alexandra Shilova; Mikhail Gilyarov; Giuseppe Biondi‐Zoccai; David E. Winchester; Christian Ukena; Michael Neuhaus; Jeroen J. Bax; Abhiram Prasad; Carlo Di Mario; Michael Böhm; Mauro Gasparini; Frank Ruschitzka; Eduardo Bossone; Rodolfo Citro; Mauro Rinaldi; Gaetano Maria De Ferrari; Thomas Lüscher; Jelena R. Ghadri; Christian Templin

    The aim of the present study was to investigate the impact of aspirin on prognosis in takotsubo syndrome (TTS).

  • Sex‐ and age‐related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long‐Term Registry
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-20
    Mitja Lainščak; Ivan Milinković; Marija Polovina; Marisa G. Crespo‐Leiro; Lars H. Lund; Stefan D. Anker; Cécile Laroche; Roberto Ferrari; Andrew J.S. Coats; Theresa McDonagh; Gerasimos Filippatos; Aldo P. Maggioni; Massimo F. Piepoli; Giuseppe M.C. Rosano; Frank Ruschitzka; Dragan Simić; Milika Ašanin; Jean‐Christophe Eicher; Mehmet B. Yilmaz; Petar M. Seferović;

    This study aimed to assess age‐ and sex‐related differences in management and 1‐year risk for all‐cause mortality and hospitalization in chronic heart failure (HF) patients.

  • Do most patients with obesity or type 2 diabetes, and atrial fibrillation, also have undiagnosed heart failure? A critical conceptual framework for understanding mechanisms and improving diagnosis and treatment
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-17
    Milton Packer

    Obesity and diabetes can lead to heart failure with preserved ejection fraction (HFpEF), potentially because they both cause expansion and inflammation of epicardial adipose tissue and thus lead to microvascular dysfunction and fibrosis of the underlying left ventricle. The same process also causes an atrial myopathy, which is clinically evident as atrial fibrillation (AF); thus, AF may be the first manifestation of HFpEF. Many patients with apparently isolated AF have latent HFpEF or subsequently develop HFpEF. Most patients with obesity or diabetes who have AF and exercise intolerance have increased left atrial pressures at rest or during exercise, even in the absence of diagnosed HFpEF. Among patients with AF, those who also have latent HFpEF have increased risk for systemic thromboembolism and death. The identification of HFpEF in patients with obesity or diabetes alters the risk‐to‐benefit relationship of commonly prescribed treatments. Bariatric surgery and statins can ameliorate AF and reduce the risk for HFpEF. Conversely, antihyperglycaemic drugs that promote adipogenesis or cause sodium retention (insulin and thiazolidinediones) may increase the risk for heart failure in patients with an underlying ventricular myopathy. Patients with obesity and diabetes who undergo catheter ablation for AF are at increased risk for AF recurrence and for post‐ablation increases in pulmonary venous pressures and worsening heart failure, especially if HFpEF coexists. Therefore, AF may be the earliest indicator of HFpEF in patients with obesity or type 2 diabetes, and recognition of HFpEF alters the management of these patients.

  • Changes in m6A RNA methylation contribute to heart failure progression by modulating translation
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-17
    Tea Berulava; Eric Buchholz; Vakhtang Elerdashvili; Tonatiuh Pena; Md Rezaul Islam; Dawid Lbik; Belal A. Mohamed; Andre Renner; Dirk von Lewinski; Michael Sacherer; Katherine E. Bohnsack; Markus T. Bohnsack; Gaurav Jain; Vincenzo Capece; Nicole Cleve; Susanne Burkhardt; Gerd Hasenfuss; Andre Fischer; Karl Toischer

    Deregulation of epigenetic processes and aberrant gene expression are important mechanisms in heart failure. Here we studied the potential relevance of m6A RNA methylation in heart failure development.

  • Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-17
    Kieran F. Docherty; Li Shen; Davide Castagno; Mark C. Petrie; William T. Abraham; Michael Böhm; Akshay S. Desai; Kenneth Dickstein; Lars V. Køber; Milton Packer; Jean L. Rouleau; Scott D. Solomon; Karl Swedberg; Ali Vazir; Michael R. Zile; Pardeep S. Jhund; John J.V. McMurray

    To investigate the relationship between heart rate and outcomes in heart failure and reduced ejection fraction (HFrEF) patients in sinus rhythm (SR) and atrial fibrillation (AF) adjusting for natriuretic peptide concentration, a powerful prognosticator.

  • Validation of the HFA‐PEFF score for the diagnosis of heart failure with preserved ejection fraction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-16
    Arantxa Barandiarán Aizpurua; Sandra Sanders‐van Wijk; Hans‐Peter Brunner‐La Rocca; Michiel Henkens; Stephane Heymans; Lauren Beussink‐Nelson; Sanjiv J. Shah; Vanessa P.M. van Empel

    Diagnosing heart failure with preserved ejection fraction (HFpEF) is challenging. The newly proposed HFA‐PEFF algorithm entails a stepwise approach. Step 1, typically performed in the ambulatory setting, establishes a pre‐test likelihood. The second step calculates a score based on echocardiography and natriuretic peptides. The aim of this study is to validate the diagnostic value and establish the clinical impact of the second step of the HFA‐PEFF score.

  • Endothelium‐dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-15
    Jeong Hoon Yang; Masaru Obokata; Yogesh N.V. Reddy; Margaret M. Redfield; Amir Lerman; Barry A. Borlaug

    Coronary microvascular inflammation is hypothesized to play a fundamental role in the pathophysiology of heart failure with preserved ejection fraction (HFpEF). No study has directly evaluated both endothelium‐dependent and independent coronary microvascular function in HFpEF.

  • Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-12
    Martin Möckel; Rudolf A. de Boer; Anna Christine Slagman; Stephan von Haehling; Morten Schou; Jörn Ole Vollert; Jan C. Wiemer; Stefan Ebmeyer; F. Javier Martín‐Sánchez; Alan S. Maisel; Evangelos Giannitsis

    To determine whether initiation of antibiotic therapy (ABX) by procalcitonin (PCT) within 8 h of admission in patients presenting to the emergency department with symptoms and signs of acute heart failure (AHF) and elevated natriuretic peptides would improve clinical outcomes.

  • Type 2 diabetes increases the long‐term risk of heart failure and mortality in patients with atrial fibrillation
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-10
    Marija Polovina, Lars H. Lund, Dijana Đikić, Ivana Petrović‐Đorđević, Gordana Krljanac, Ivan Milinković, Ivana Veljić, Massimo F. Piepoli, Giuseppe M.C. Rosano, Arsen D. Ristić, Milika Ašanin, Petar M. Seferović

    Impact of type 2 diabetes mellitus (T2DM) on non‐thromboembolic outcomes in atrial fibrillation (AF) is insufficiently explored. This prospective cohort study of AF patients aimed (i) to analyse the association between T2DM and heart failure (HF) events (including new‐onset HF), and all‐cause and cardiovascular mortality, (ii) to assess the impact of baseline T2DM treatment on outcomes, and (iii) to explore characteristics of new‐onset HF phenotypes in relation to T2DM status.

  • Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-09
    Michael Böhm, Jonathan Slawik, Martina Brueckmann, Michaela Mattheus, Jyothis T. George, Anne Pernille Ofstad, Silvio E. Inzucchi, David Fitchett, Stefan D. Anker, Nikolaus Marx, Christoph Wanner, Bernard Zinman, Subodh Verma

    Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA‐REG OUTCOME trial explores CV and renal outcomes in patients with vs. without AF at baseline and assesses the benefits of empagliflozin.

  • Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-09
    Michele Senni, Rolf Wachter, Klaus K. Witte, Ewa Straburzynska‐Migaj, Jan Belohlavek, Candida Fonseca, Christian Mueller, Eva Lonn, Arhit Chakrabarti, Weibin Bao, Adele Noe, Heike Schwende, Dmytro Butylin, Domingo Pascual‐Figal,

    Sacubitril/valsartan has shown efficacy and tolerability in patients with heart failure (HF) and reduced ejection fraction (HFrEF) in the ambulatory setting (PARADIGM‐HF), and following stabilisation of acutely decompensated HF (ADHF) (PIONEER‐HF and TRANSITION). However, data are lacking for the initiation of sacubitril/valsartan in newly diagnosed (de novo) HFrEF. Here, we assess the tolerability of initiating sacubitril/valsartan following ADHF in TRANSITION subgroups of patients with a de novo vs. prior diagnosis of HFrEF.

  • Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-09
    Burkert Pieske, Mahesh J. Patel, Cynthia M. Westerhout, Kevin J. Anstrom, Javed Butler, Justin Ezekowitz, Adrian F. Hernandez, Joerg Koglin, Carolyn S.P. Lam, Piotr Ponikowski, Lothar Roessig, Adriaan A. Voors, Christopher M. O'Connor, Paul W. Armstrong,

    Describe the distinguishing features of heart failure (HF) patients with reduced ejection fraction (HFrEF) in the VICTORIA (Vericiguat Global Study in Patients with Heart Failure with Reduced Ejection Fraction) trial.

  • Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-09
    Li Li, Rong Liu, Chao Jiang, Xin Du, Mark D. Huffman, Carolyn S.P. Lam, Anushka Patel, Graham S. Hillis, Craig S. Anderson, Changsheng Ma, Xiaoyan Zhao, Xiaofang Wang, Ling Li, Jianzeng Dong

    Registry studies in high‐income countries have defined contemporary management of heart failure (HF), but few such data exist in the large aging population of China. We report the study design and baseline characteristics of the Heart Failure Registry of Patient Outcomes (HERO) study, undertaken to determine evidence–practice gaps in the management of HF in a broad and representative population of China.

  • Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-09
    Jelena Čelutkienė, Mitja Lainscak, Lisa Anderson, Etienne Gayat, Julia Grapsa, Veli‐Pekka Harjola, Robert Manka, Petros Nihoyannopoulos, Pasquale Perrone Filardi, Rosa Vrettou, Stefan D. Anker, Gerasimos Filippatos, Alexandre Mebazaa, Marco Metra, Massimo Piepoli, Frank Ruschitzka, Jose Luis Zamorano, Giuseppe Rosano, Petar Seferovic

    Acute heart failure is one of the main diagnostic and therapeutic challenges in clinical practice due to a non‐specific clinical manifestation and the urgent need for timely and tailored management at the same time. In this position statement, the Heart Failure Association aims to systematize the use of various imaging methods in accordance with the timeline of acute heart failure care proposed in the recent guidelines of the European Society of Cardiology. During the first hours of admission the point‐of‐care focused cardiac and lung ultrasound examination is an invaluable tool for rapid differential diagnosis of acute dyspnoea, which is highly feasible and relatively easy to learn. Several portable and stationary imaging modalities are being increasingly used for the evaluation of cardiac structure and function, haemodynamic and volume status, precipitating myocardial ischaemia or valvular abnormalities, and systemic and pulmonary congestion. This paper emphasizes the central role of the full echocardiographic examination in the identification of heart failure aetiology, severity of cardiac dysfunction, indications for specific heart failure therapy, and risk stratification. Correct evaluation of cardiac filling pressures and accurate prognostication may help to prevent unscheduled short‐term readmission. Alternative advanced imaging modalities should be considered to assist patient management in the pre‐ and post‐discharge phase, including cardiac magnetic resonance, computed tomography, nuclear studies, and coronary angiography. The Heart Failure Association addresses this paper to the wide spectrum of acute care and heart failure specialists, highlighting the value of all available imaging techniques at specific stages and in common clinical scenarios of acute heart failure.

  • European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-09
    Petar M. Seferović, Andrew J.S. Coats, Piotr Ponikowski, Gerasimos Filippatos, Martin Huelsmann, Pardeep S. Jhund, Marija M. Polovina, Michel Komajda, Jelena Seferović, Ibrahim Sari, Francesco Cosentino, Giuseppe Ambrosio, Marco Metra, Massimo Piepoli, Ovidiu Chioncel, Lars H. Lund, Thomas Thum, Rudolf A. De Boer, Wilfried Mullens, Yuri Lopatin, Maurizio Volterrani, Loreena Hill, Johann Bauersachs, Alexander Lyon, Mark C. Petrie, Stefan Anker, Giuseppe M.C. Rosano

    Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and associated with considerable morbidity and mortality. Significant advances have recently occurred in the treatment of T2DM, with evidence of several new glucose‐lowering medications showing either neutral or beneficial cardiovascular effects. However, some of these agents have safety characteristics with strong practical implications in HF [i.e. dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA), and sodium–glucose co‐transporter type 2 (SGLT‐2) inhibitors].

  • Selenium and outcome in heart failure
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-06
    Nils Bomer, Niels Grote Beverborg, Martijn F. Hoes, Koen W. Streng, Mathilde Vermeer, Martin M. Dokter, Jan IJmker, Stefan D. Anker, John G.F. Cleland, Hans L. Hillege, Chim C. Lang, Leong L. Ng, Nilesh J. Samani, Jasper Tromp, Dirk J. van Veldhuisen, Daan J. Touw, Adriaan A. Voors, Peter van der Meer

    Severe deficiency of the essential trace element selenium can cause myocardial dysfunction although the mechanism at cellular level is uncertain. Whether, in clinical practice, moderate selenium deficiency is associated with worse symptoms and outcome in patients with heart failure is unknown.

  • Mid‐regional pro‐adrenomedullin outperforms N‐terminal pro‐B‐type natriuretic peptide for the diagnosis of acute heart failure in the presence of atrial fibrillation
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-06
    Win Sen Kuan, Irwani Ibrahim, Siew Pang Chan, Zisheng Li, Oi Wah Liew, Chris Frampton, Richard Troughton, Chris J. Pemberton, Jenny Pek Ching Chong, Li Ling Tan, Weiqin Lin, Shirley Beng Suat Ooi, A. Mark Richards

    The performance of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) in diagnosing acute decompensated heart failure (ADHF) among patients presenting with breathlessness is markedly impaired in the presence of atrial fibrillation (AF). We evaluated the diagnostic performance of mid‐regional pro‐adrenomedullin (MR‐proADM) and cardiac troponin T as possible alternative markers for discrimination of ADHF in this setting.

  • Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-03
    Paloma Pandhi, Jozine M. ter Maaten, Johanna E. Emmens, Joachim Struck, Andreas Bergmann, John G. Cleland, Michael M. Givertz, Marco Metra, Christopher M. O'Connor, John R. Teerlink, Piotr Ponikowski, Gad Cotter, Beth Davison, Dirk J. van Veldhuisen, Adriaan A. Voors

    Recently, bio‐adrenomedullin (bio‐ADM) was proposed as a congestion marker in heart failure (HF). In the present study, we aimed to study whether bio‐ADM levels at discharge from a hospital admission for worsening HF could provide additional information on (residual) congestion status, diuretic dose titration and clinical outcomes.

  • The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-03
    Martijn F. Hoes, Jasper Tromp, Wouter Ouwerkerk, Nils Bomer, Silke U. Oberdorf‐Maass, Nilesh J. Samani, Leong L. Ng, Chim C. Lang, Pim van der Harst, Hans Hillege, Stefan D. Anker, Marco Metra, Dirk J. van Veldhuisen, Adriaan A. Voors, Peter van der Meer

    Cathepsin D is a ubiquitous lysosomal protease that is primarily secreted due to oxidative stress. The role of circulating cathepsin D in heart failure (HF) is unknown. The aim of this study is to determine the association between circulating cathepsin D levels and clinical outcomes in patients with HF and to investigate the biological settings that induce the release of cathepsin D in HF.

  • Less invasive ventricular reconstruction for ischaemic heart failure
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-03
    Patrick Klein, Stefan D. Anker, Andrew Wechsler, Ivo Skalsky, Petr Neuzil, Lon S. Annest, Mauro Bifi, Theresa McDonagh, Christian Frerker, Tobias Schmidt, Horst Sievert, Anthony N. Demaria, Sebastian Kelle

    Surgical ventricular reconstruction to remodel, reshape, and reduce ventricular volume is an effective therapy in selected patients with chronic heart failure (HF) of ischaemic aetiology. The BioVentrix Revivent TC System offers efficacy comparable to conventional surgical ventricular reconstruction and is less invasive utilizing micro‐anchor pairs to exclude scarred myocardium on the beating heart. Here, we present 12‐months follow‐up data of an international multicenter study.

  • Cardiovascular and non‐cardiovascular death distinction: the utility of troponin beyond N‐terminal pro‐B‐type natriuretic peptide. Findings from the BIOSTAT‐CHF study
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-02
    João Pedro Ferreira, Wouter Ouwerkerk, Jasper Tromp, Leong Ng, Kenneth Dickstein, Stefan Anker, Gerasimos Filippatos, John G. Cleland, Marco Metra, Dirk J. van Veldhuisen, Adriaan A. Voors, Faiez Zannad

    Heart failure (HF) patients are at high‐risk of cardiovascular (CV) events, including CV death. Nonetheless, a substantial proportion of these patients die from non‐CV causes. Identifying patients at higher risk for each individual event may help selecting patients for clinical trials and tailoring cardiovascular therapies. The aims of the present study are to: (i) characterize patients according to CV vs. non‐CV death; (ii) develop models for the prediction of the respective events; (iii) assess the models' performance to differentiate CV from non‐CV death.

  • Mitral regurgitation, left atrial structural and functional remodelling and the effect on pulmonary haemodynamics
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-12-02
    Riccardo M. Inciardi, Andrea Rossi, Corinna Bergamini, Giovanni Benfari, Caterina Maffeis, Carmen Greco, Andrea Drago, Marco Guazzi, Flavio L. Ribichini, Mariantonietta Cicoira

    To assess the association between mitral regurgitation (MR) and left atrial (LA) structural and functional remodelling and their effect on pulmonary haemodynamics.

  • Pulmonary artery pulsatility index: physiological basis and clinical application
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-28
    Hoong Sern Lim, Finn Gustafsson

    Pulmonary artery pulsatility index (PAPi) is a haemodynamic parameter that is derived from right atrial and pulmonary artery pulse pressures. A number of reports have described the prognostic value of PAPi in patients with advanced heart failure and cardiogenic shock. However, the derivation and physiological interpretation of this parameter have received little attention. This review will examine the physiological interpretation and clinical data for PAPi.

  • Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and mid‐range ejection fraction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-28
    Sara Rovai, Ugo Corrà, Massimo Piepoli, Carlo Vignati, Elisabetta Salvioni, Alice Bonomi, Irene Mattavelli, Luca Arcari, Angela B. Scardovi, Pasquale Perrone Filardi, Rocco Lagioia, Stefania Paolillo, Damiano Magrì, Giuseppe Limongelli, Marco Metra, Michele Senni, Domenico Scrutinio, Rosa Raimondo, Michele Emdin, Carlo Lombardi, Gaia Cattadori, Gianfranco Parati, Federica Re, Mariantonietta Cicoira, Giovanni Q. Villani, Chiara Minà, Michele Correale, Maria Frigerio, Enrico Perna, Massimo Mapelli, Alessandra Magini, Francesco Clemenza, Maurizio Bussotti, Elisa Battaia, Marco Guazzi, Francesco Bandera, Roberto Badagliacca, Andrea Di Lenarda, Giuseppe Pacileo, Aldo Maggioni, Claudio Passino, Susanna Sciomer, Gianfranco Sinagra, Piergiuseppe Agostoni,

    Exercise oscillatory ventilation (EOV) is a pivotal cardiopulmonary exercise test parameter for the prognostic evaluation of patients with chronic heart failure (HF). It has been described in patients with HF with reduced ejection fraction (<40%, HFrEF) and with HF with preserved ejection fraction (>50%, HFpEF), but no data are available for patients with HF with mid‐range ejection fraction (40–49%, HFmrEF). The aim of the study was to evaluate the prognostic role of EOV in HFmrEF patients.

  • Left atrial structure and function and the risk of death or heart failure in atrial fibrillation
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-27
    Riccardo M. Inciardi, Robert P. Giugliano, Brian Claggett, Deepak K. Gupta, Alvin Chandra, Christian T. Ruff , Elliott M. Antman, Michele F. Mercuri, Michael A. Grosso, Eugene Braunwald, Scott D. Solomon,

    The present study aimed to assess the association between left atrial (LA) structure and function and the risk for cardiovascular (CV) death or heart failure (HF) hospitalization in a population with atrial fibrillation (AF).

  • B‐type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-25
    Nicholas Wettersten, Yu Horiuchi, Dirk J. van Veldhuisen, Christian Mueller, Gerasimos Filippatos, Richard Nowak, Christopher Hogan, Michael C. Kontos, Chad M. Cannon, Gerhard A. Müeller, Robert Birkhahn, Pam Taub, Gary M. Vilke, Olga Barnett, Kenneth McDonald, Niall Mahon, Julio Nuñez, Carlo Briguori, Claudio Passino, Patrick T. Murray, Alan Maisel

    In acute heart failure (AHF), relationships between changes in B‐type natriuretic peptide (BNP) and worsening renal function (WRF) and its prognostic implications have not been fully determined. We investigated the relationship between WRF and a decrease in BNP with in‐hospital and 1‐year mortality in AHF.

  • Long‐term effects of Na+/Ca2+ exchanger inhibition with ORM‐11035 improves cardiac function and remodelling without lowering blood pressure in a model of heart failure with preserved ejection fraction
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-24
    Uwe Primessnig, Taja Bracic, Jouko Levijoki, Leena Otsomaa, Piero Pollesello, Martin Falcke, Burkert Pieske, Frank R. Heinzel

    Heart failure with preserved ejection fraction (HFpEF) is increasingly common but there is currently no established pharmacological therapy. We hypothesized that ORM‐11035, a novel specific Na+/Ca2+ exchanger (NCX) inhibitor, improves cardiac function and remodelling independent of effects on arterial blood pressure in a model of cardiorenal HFpEF.

  • Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2 years
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-18
    Bernard Iung, Xavier Armoiry, Alec Vahanian, Florent Boutitie, Nathan Mewton, Jean‐Noël Trochu, Thierry Lefèvre, David Messika‐Zeitoun, Patrice Guerin, Bertrand Cormier, Eric Brochet, Hélène Thibault, Dominique Himbert, Sophie Thivolet, Guillaume Leurent, Guillaume Bonnet, Erwan Donal, Nicolas Piriou, Christophe Piot, Gilbert Habib, Frédéric Rouleau, Didier Carrié, Mohammed Nejjari, Patrick Ohlmann, Christophe Saint Etienne, Lionel Leroux, Martine Gilard, Géraldine Samson, Gilles Rioufol, Delphine Maucort‐Boulch, Jean François Obadia,

    The MITRA‐FR trial showed that among symptomatic patients with severe secondary mitral regurgitation, percutaneous repair did not reduce the risk of death or hospitalization for heart failure at 12 months compared with guideline‐directed medical treatment alone. We report the 24‐month outcome from this trial.

  • The economic burden of heart failure in Denmark from 1998 to 2016
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-07-29
    Johan S. Bundgaard, Ulrik M. Mogensen, Stefan Christensen, Uffe Ploug, Rasmus Rørth, Rikke Ibsen, Jakob Kjellberg, Lars Køber

    Heart failure (HF) imposes a large burden on both the individual and the society. The aim of this study was to investigate the economic burden (either direct or indirect costs) attributed to patients with HF before, at, and after time of diagnosis.

  • Temporal trends in incidence and patient characteristics in cardiogenic shock following acute myocardial infarction from 2010 to 2017: a Danish cohort study
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-07-24
    Ole K.L. Helgestad, Jakob Josiassen, Christian Hassager, Lisette O. Jensen, Lene Holmvang, Anne Sørensen, Martin Frydland, Annmarie T. Lassen, Nanna L.J. Udesen, Henrik Schmidt, Hanne B. Ravn, Jacob E. Møller

    We sought to describe the contemporary annual incidence of cardiogenic shock (CS) following acute myocardial infarction (AMICS), the proportion of patients developing CS following ST‐elevation myocardial infarction (STEMI), and other temporal changes in AMICS in Denmark between 2010 and 2017.

  • Cancer and heart disease: associations and relations
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-07-18
    Rudolf A. de Boer, Wouter C. Meijers, Peter van der Meer, Dirk J. van Veldhuisen

    Emerging evidence supports that cancer incidence is increased in patients with cardiovascular (CV) disease and heart failure (HF), and patients with HF frequently die from cancer. Recently, data have been generated showing that circulating factors in relation to HF promote tumour growth and development in murine models, providing proof that a causal relationship exists between both diseases. Several common pathophysiological mechanisms linking HF to cancer exist, and include inflammation, neuro‐hormonal activation, oxidative stress and a dysfunctional immune system. These shared mechanisms, in combination with risk factors, in concert may explain why patients with HF are prone to develop cancer. Investigating the new insights linking HF with cancer is rapidly becoming an exciting new field of research, and we herein review the most recent data. Besides insights in mechanisms, we call for clinical awareness, that is essential to optimize treatment strategies of patients having developed cancer with a history of HF. Finally, ongoing and future trials should strive for comprehensive phenotyping of both CV and cancer end points, to allow optimal usefulness of data, and to better describe and understand common characteristics of these two lethal diseases.

  • The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-07-15
    John J.V. McMurray, David L. DeMets, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Anna Maria Langkilde, Felipe A. Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S. Sabatine, Mikaela Sjöstrand, Scott D. Solomon,

    The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial, (ii) compare DAPA‐HF patients to participants in contemporary heart failure (HF) registries and in other recent HF trials, and (iii) compare individuals with diabetes, pre‐diabetes and a normal glycated haemoglobin (HbA1c) in DAPA‐HF.

  • Sacubitril/valsartan eligibility and outcomes in the ESC‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-06-18
    Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, Cécile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carlos Aguiar, Jan Murin, Przemyslaw Leszek, Theresa McDonagh, Aldo P. Maggioni, Lars H. Lund,

    To assess the proportion of patients with heart failure and reduced ejection fraction (HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines Agency/Food and Drug Administration (EMA/FDA) label, the PARADIGM‐HF trial and the 2016 ESC guidelines, and the association between eligibility and outcomes.

  • Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-06-18
    Patricia Javaloyes, Òscar Miró, Víctor Gil, Francisco Javier Martín‐Sánchez, Javier Jacob, Pablo Herrero, Koji Takagi, Aitor Alquézar‐Arbé, María Pilar López Díez, Enrique Martín, Carlos Bibiano, Rosa Escoda, Cristina Gil, Marta Fuentes, Guillermo Llopis García, José María Álvarez Pérez, Alba Jerez, Josep Tost, Lluís Llauger, Rodolfo Romero, José Manuel Garrido, Esther Rodríguez‐Adrada, Carolina Sánchez, Xavier Rossello, John Parissis, Alexandre Mebazaa, Ovidiu Chioncel, Pere Llorens,

    To compare the clinical characteristics and outcomes of patients with acute heart failure (AHF) according to clinical profiles based on congestion and perfusion determined in the emergency department (ED).

  • Biomarker guidance allows a more personalized allocation of patients for remote patient management in heart failure: results from the TIM‐HF2 trial
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-06-17
    Martin Möckel, Kerstin Koehler, Stefan D. Anker, Jörn Vollert, Volker Moeller, Magdalena Koehler, Stefan Gehrig, Jan C. Wiemer, Stephan von Haehling, Friedrich Koehler

    The TIM‐HF2 study showed less days lost due to unplanned cardiovascular hospitalization or all‐cause death and improved survival in patients randomly assigned to remote patient management (RPM) instead of standard of care.

  • Acute heart failure congestion and perfusion status – impact of the clinical classification on in‐hospital and long‐term outcomes; insights from the ESC‐EORP‐HFA Heart Failure Long‐Term Registry
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-05-24
    Ovidiu Chioncel, Alexandre Mebazaa, Aldo P. Maggioni, Veli‐Pekka Harjola, Giuseppe Rosano, Cecile Laroche, Massimo F. Piepoli, Maria G. Crespo‐Leiro, Mitja Lainscak, Piotr Ponikowski, Gerasimos Filippatos, Frank Ruschitzka, Petar Seferovic, Andrew J.S. Coats, Lars H. Lund,

    Classification of acute heart failure (AHF) patients into four clinical profiles defined by evidence of congestion and perfusion is advocated by the 2016 European Society of Cardiology (ESC)guidelines. Based on the ESC‐EORP‐HFA Heart Failure Long‐Term Registry, we compared differences in baseline characteristics, in‐hospital management and outcomes among congestion/perfusion profiles using this classification.

  • Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-05-09
    Frederik H. Verbrugge, Pieter Martens, Koen Ameloot, Veerle Haemels, Joris Penders, Matthias Dupont, Wai Hong Wilson Tang, Walter Droogné, Wilfried Mullens

    To investigate the effects of acetazolamide on natriuresis, decongestion, kidney function and neurohumoral activation in acute heart failure (AHF).

  • Long‐term follow‐up in peripartum cardiomyopathy patients with contemporary treatment: low mortality, high cardiac recovery, but significant cardiovascular co‐morbidities
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-13
    Valeska Moulig, Tobias Jonathan Pfeffer, Melanie Ricke‐Hoch, Stella Schlothauer, Tobias Koenig, Johannes Schwab, Dominik Berliner, Roman Pfister, Guido Michels, Arash Haghikia, Christine S. Falk, David Duncker, Christian Veltmann, Denise Hilfiker‐Kleiner, Johann Bauersachs

    Peripartum cardiomyopathy (PPCM) establishes late in pregnancy or in the first postpartum months. Many patients recover well within the first year, but long‐term outcome studies on morbidity and mortality are rare. Here, we present 5‐year follow‐up data of a German PPCM cohort.

  • Improving risk prediction in heart failure using machine learning
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-12
    Eric D. Adler, Adriaan A. Voors, Liviu Klein, Fima Macheret, Oscar O. Braun, Marcus A. Urey, Wenhong Zhu, Iziah Sama, Matevz Tadel, Claudio Campagnari, Barry Greenberg, Avi Yagil

    Predicting mortality is important in patients with heart failure (HF). However, current strategies for predicting risk are only modestly successful, likely because they are derived from statistical analysis methods that fail to capture prognostic information in large data sets containing multi‐dimensional interactions.

  • Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta‐analysis
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-12
    Lars Michel, Raluca I. Mincu, Amir A. Mahabadi, Stephan Settelmeier, Fadi Al‐Rashid, Tienush Rassaf, Matthias Totzeck

    Cardiac biomarkers are a mainstay in diagnosis of cardiovascular disease but their role in cardio‐oncology has not yet been systematically evaluated. This meta‐analysis aims to determine whether cardiac troponins and (N‐terminal pro) brain natriuretic peptide (BNP/NT‐proBNP) predict cancer therapy‐related left ventricular (LV) dysfunction.

  • Heart failure after treatment for breast cancer
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-12
    Naomi B. Boekel, Fran K. Duane, Judy N. Jacobse, Michael Hauptmann, Michael Schaapveld, Gabe S. Sonke, Jourik A. Gietema, Maartje J. Hooning, Caroline M. Seynaeve, Angela H.E.M. Maas, Sarah C. Darby, Berthe M.P. Aleman, Carolyn W. Taylor, Flora E. van Leeuwen

    We aimed to develop dose–response relationships for heart failure (HF) following radiation and anthracyclines in breast cancer treatment, and to assess HF associations with trastuzumab and endocrine therapies.

  • Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
    Eur. J. Heart Fail. (IF 13.965) Pub Date : 2019-11-11
    Jan F. Nauta, Yoran M. Hummel, Jasper Tromp, Wouter Ouwerkerk, Peter van der Meer, Xuanyi Jin, Carolyn S.P. Lam, Jeroen J. Bax, Marco Metra, Nilesh J. Samani, Piotr Ponikowski, Kenneth Dickstein, Stefan D. Anker, Chim C. Lang, Leong L. Ng, Faiez Zannad, Gerasimos S. Filippatos, Dirk J. van Veldhuisen, Joost P. van Melle, Adriaan A. Voors

    Heart failure is traditionally classified by left ventricular ejection fraction (LVEF), rather than by left ventricular (LV) geometry, with guideline‐recommended therapies in heart failure with reduced ejection fraction (HFrEF) but not heart failure with preserved ejection fraction (HFpEF). Most patients with HFrEF have eccentric LV hypertrophy, but some have concentric LV hypertrophy. We aimed to compare clinical characteristics, biomarker patterns, and response to treatment of patients with HFrEF and eccentric vs. concentric LV hypertrophy.

Contents have been reproduced by permission of the publishers.